Septerna, Inc.
250 East Grand Avenue
Suite 65
South San Francisco
CA
94080
United States
7 articles about Septerna, Inc.
-
Septerna to Participate in Upcoming Investor and Industry Conferences
2/22/2024
Septerna today announced that members of the management team, including Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder, and Liz Bhatt, MS, MBA, Chief Operating Officer, will participate in the following investor and industry conferences.
-
Septerna Announces Novel GPCR-targeted Program Acquired by Vertex
9/12/2023
Septerna today announced that it has signed a definitive asset purchase agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired an undisclosed discovery-stage GPCR program.
-
Septerna Bolsters Leadership Team as the Company Advances its Multi-Product Pipeline Toward Clinical Studies
8/31/2023
Septerna announced the addition of David Martin, Ph.D., as Senior Vice President of Development Sciences, and Samira Shaikhly as Chief People Officer to its leadership team.
-
Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines
7/11/2023
Septerna, a biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors, announced the closing of a $150 million Series B financing.
-
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
-
Septerna Announces the Formation of a Cross-Functional Scientific and Drug Discovery Advisory Board
12/19/2022
Septerna today announced the establishment of its cross-functional scientific and drug discovery advisory board with seasoned industry drug hunters and leading academic GPCR biology and pharmacology scientists.
-
After reaching a record high in 2021, venture capital dollars have tailed off in the biopharma industry in 2022. That said, a few biopharma hotbeds have still seen sizeable launch rounds.